These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1946931)

  • 1. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
    Ostlere L; Warner T; Meunier PJ; Hulme P; Hesp R; Watts RW; Reeve J
    Q J Med; 1991 Jun; 79(290):503-15. PubMed ID: 1946931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
    Ciana G; Cuttini M; Bembi B
    N Engl J Med; 1997 Sep; 337(10):712. PubMed ID: 9280823
    [No Abstract]   [Full Text] [Related]  

  • 3. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate.
    Harinck HI; Bijvoet OL; van der Meer JW; Jones B; Onvlee GJ
    Lancet; 1984 Sep; 2(8401):513. PubMed ID: 6147561
    [No Abstract]   [Full Text] [Related]  

  • 4. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.
    Bembi B; Agosti E; Boehm P; Nassimbeni G; Zanatta M; Vidoni L
    Acta Paediatr; 1994 Jan; 83(1):122-4. PubMed ID: 8193463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.
    Samuel R; Katz K; Papapoulos SE; Yosipovitch Z; Zaizov R; Liberman UA
    Pediatrics; 1994 Sep; 94(3):385-9. PubMed ID: 8065868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
    Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Peracute osseous disease course in a case of cerebroside lipoidosis (Gaucher's disease) in an adult].
    Jesserer H; Bazant F; Kaiser E; Zeitlhofer J
    Wien Z Inn Med; 1967; 48(8):312-23. PubMed ID: 5620592
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaucher's disease: orthopaedic considerations.
    Siffert RS; Platt A
    Prog Clin Biol Res; 1982; 95():617-24. PubMed ID: 7122641
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.
    Maas M; Hollak CE; Akkerman EM; Aerts JM; Stoker J; Den Heeten GJ
    AJR Am J Roentgenol; 2002 Oct; 179(4):961-5. PubMed ID: 12239046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loosening of a noncemented porous-coated anatomic femoral component in Gaucher's disease. A case report and review of literature.
    van Wellen PA; Haentjens P; Frecourt N; Opdecam P
    Acta Orthop Belg; 1994; 60(1):119-23. PubMed ID: 8171981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease.
    Brady K; Corash L; Bhargava V
    Arch Pathol Lab Med; 1997 Oct; 121(10):1108-11. PubMed ID: 9341594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An adult form of type-I. Gaucher's disease].
    Múzes G; Pitlik E; Gohér A; Somogyi A; Tulassay Z
    Orv Hetil; 2000 Mar; 141(13):669-73. PubMed ID: 10774238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher's disease: unexpected diagnosis in three patients over seventy years old.
    Berrebi A; Wishnitzer R; Von-der-Walde U
    Nouv Rev Fr Hematol (1978); 1984; 26(3):201-3. PubMed ID: 6739289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative indications for bisphosphonate therapy.
    Landesberg R; Eisig S; Fennoy I; Siris E
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
    de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
    Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.